Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes

Abstract

Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.